Lonza and Crucell in cell culture medium marketing partnership
Lonza has agreed to manufacture, market and sell a cell culture medium developed by Crucell.
Lonza has agreed to manufacture, market and sell a cell culture medium developed by Crucell.
The PERMEXCISTM cell culture medium, developed by global biopharma company Crucell NV for PER.C6 cells, is a chemically defined cell culture medium that does not contain human- or animal-derived components.
The PERMEXCISTM medium has been designed for use in the large-scale manufacture of biopharmaceutical products, including vaccines. This novel medium has proven, in a comparison study performed by Crucell, to provide higher viral vaccine product yields in PER.C6-based manufacturing processes than some of the currently marketed
media for PER.C6 cells. "Lonza is pleased to enter into this agreement with Crucell N.V. Lonza is a leader in cell culture technology and media manufacturing, with a broad range of specialised media for all the major cell lines used in the biopharmaceutical industry. The new PER.C6 medium is a complementary addition to the Lonza Serum Free Medium product range," said Roel Gordijn, global sales and marketing director for media in the bioscience business of Lonza.